You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBeclomethasone dipropionate
Accession NumberDB00394  (APRD00564)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionBeclomethasone dipropionate is a prodrug of the free form, Beclomethasone (beclomethasone-17-monopropionate). An anti-inflammatory, synthetic corticosteroid, it is used topically as an anti-inflammatory agent and in aerosol form for the treatment of asthma and allergic rhinitis (seasonal and perennial). Beclometasone dipropionate is also being investigated for oral treatment in mild-to-moderate Crohn's disease of ileal or ileal-right colonic localisation and for "topical" use mild-to-moderate graft versus host disease. It is marketed under several brand names such as Qnasl (US) and Rivanase AQ (Canada).
Structure
Thumb
Synonyms
(11beta,16beta)-9-chloro-11-Hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione
9-chloro-11beta-Hydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
9-chloro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione
9-chloro-16beta-Methyl-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate
9α-chloro-16β-methylprednisolone
Beclometasone
Beclometasone 17,21-dipropionate
Beclometasone dipropionate
Beclomethasone dipropionate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-beclomethasone Dipropionate Inhaler 50mcg/mdmetered-dose aerosol50 mcginhalationAltimed Pharma Inc.1992-12-312005-05-27Canada
Beclodisk - Pwr Inh 100mcg/blisterpowder100 mcginhalationGlaxo Wellcome Inc.1997-09-032000-05-24Canada
Beclodisk - Pwr Inh 200mcg/blisterpowder200 mcginhalationGlaxo Wellcome Inc.1997-06-112000-05-24Canada
Beclodisk Pwr 100mcg/blisterpowder100 mcginhalationGlaxo Canada Inc1989-12-311998-07-30Canada
Beclodisk Pwr 200mcg/blisterpowder200 mcginhalationGlaxo Canada Inc1989-12-311998-07-30Canada
Becloforte 250mcg/aemmetered-dose aerosol250 mcginhalationGlaxo Canada Inc1988-12-311998-07-30Canada
Becloforte Inhaler - Aem Inh 250mcg/aemmetered-dose aerosol250 mcginhalationGlaxo Wellcome Inc.1997-02-112000-05-24Canada
Beclomethasone Aqueous Nasal Spray 50mcg/metered Dosemetered-dose aerosol; suspension50 mcgnasalPrempharm Inc1997-01-052005-08-05Canada
Beclomethasone Dipropionate Nas-spr 50mcg/aemmetered-dose aerosol50 mcgnasalKenral Inc.1992-12-311997-08-11Canada
Beclomethasone Dipropionate Nasal Inhalermetered-dose aerosol50 mcginhalation; nasalPharmaco Canada Inc.1994-12-312001-07-18Canada
Beclomethasone Dipropionate Oral Inhalermetered-dose aerosol50 mcginhalation; oralPharmaco Canada Inc.1994-12-312001-07-18Canada
Beclovent - Aem 50mcg/aemmetered-dose aerosol50 mcginhalationGlaxo Wellcome Inc.1998-03-302000-05-24Canada
Beclovent Aem 50mcg/aemmetered-dose aerosol50 mcginhalationGlaxo Canada Inc1975-12-311998-07-30Canada
Beclovent Rotacaps - Inh 100mcg/capsulecapsule100 mcginhalationGlaxo Wellcome Inc.1998-11-302000-05-24Canada
Beclovent Rotacaps - Inh 200mcg/capcapsule200 mcginhalationGlaxo Wellcome Inc.1998-03-302000-05-24Canada
Beclovent Rotacaps 100mcgcapsule100 mcginhalationGlaxo Canada Inc1985-12-312000-08-02Canada
Beclovent Rotacaps 200mcgcapsule200 mcginhalationGlaxo Canada Inc1985-12-311998-07-30Canada
Beconase AQspray, suspension42 ug/1nasalGlaxo Smith Kline Llc1989-10-01Not applicableUs
Beconase AQspray, suspension42 ug/1nasalSTAT Rx USA LLC1989-10-01Not applicableUs
Beconase AQspray, suspension42 ug/1nasalA S Medication Solutions Llc1989-10-01Not applicableUs
Beconase AQ Nasal Aem 50mcg/aemmetered-dose aerosol50 mcgnasalGlaxo Canada Inc1991-12-312000-05-24Canada
Beconase Nasal Aem 50mcg/aemmetered-dose aerosol50 mcgnasalGlaxo Canada Inc1991-12-311996-09-10Canada
Mylan-beclo AQmetered-dose aerosol; suspension50 mcgnasalMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Nu-beclomethasone 50 Mcg/metered Nasal Spraysuspension50 mcgnasalNu Pharm Inc1998-11-242012-09-04Canada
Propadermcream0.025 %topicalValeant Canada Lp/valeant Canada s.e.c.1998-03-30Not applicableCanada
Propaderm Cream 0.025%cream.025 %topicalAllen & Hanburys A Glaxo Canada Ltd. Co.1989-12-151998-07-29Canada
Propaderm Lot 0.025%lotion.025 %topicalAllen & Hanburys A Glaxo Canada Ltd. Co.1973-12-311996-09-10Canada
Propaderm Lotion 0.025%lotion0.025 %topicalShire Biochem Inc1996-07-302005-12-09Canada
Qnaslaerosol, metered40 ug/1nasalTeva Respiratory, LLC2015-02-01Not applicableUs
Qnaslaerosol, metered80 ug/1nasalTeva Respiratory, LLC2012-04-13Not applicableUs
Qvaraerosol, metered80 ug/1respiratory (inhalation)Teva Respiratory, LLC2011-01-21Not applicableUs
Qvaraerosol, metered40 ug/1respiratory (inhalation)Physicians Total Care, Inc.2008-01-29Not applicableUs
Qvaraerosol, metered80 ug/1respiratory (inhalation)Physicians Total Care, Inc.2008-01-29Not applicableUs
Qvaraerosol, metered40 ug/1respiratory (inhalation)STAT Rx USA LLC2000-09-15Not applicableUs
Qvarmetered-dose aerosol50 mcginhalationValeant Canada Lp Valeant Canada S.E.C.2000-05-29Not applicableCanada
Qvaraerosol, metered40 ug/1respiratory (inhalation)Teva Respiratory, LLC2011-01-19Not applicableUs
Qvaraerosol, metered40 ug/1respiratory (inhalation)Teva Respiratory, LLC2000-10-062015-11-30Us
Qvarmetered-dose aerosol100 mcginhalationValeant Canada Lp Valeant Canada S.E.C.2000-05-29Not applicableCanada
Ratio-beclomethasone AQspray50 mcgnasalRatiopharm Inc Division Of Teva Canada Limited1995-12-312010-05-21Canada
Rivanase AQ.nasal Spray 50mcg/metered Dosemetered-dose aerosol50 mcgnasalLaboratoire Riva Inc1997-08-27Not applicableCanada
Vancenase Aer 50mcgmetered-dose aerosol50 mcginhalation; nasalSchering Plough Canada Inc1978-12-312001-07-18Canada
Vanceril Aem 50mcgmetered-dose aerosol50 mcginhalation; oralSchering Plough Canada Inc1976-12-312004-07-21Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-beclomethasone Nasal Spraysuspension50 mcgnasalApotex Inc1998-10-07Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AerobecTeva
AldecinSchering-Plough
AnceronNot Available
AndionNot Available
BeclacinMayado Seiyaku
BecloforteGlaxoSmithKline
BeclometOrion
BeclorhinolChiesi
BeclovalNot Available
BecloventGlaxoSmithKline
BecodisksGlaxoSmithKline
BeconaseGlaxoSmithKline
BeconasolNot Available
BecotideGlaxoSmithKline
Clenil-ANot Available
EntydermaNot Available
InaloneGlaxoSmithKline
KorbutoneNot Available
orBecDOR BioPharma, Inc.
Rino-ClenilChiesi
RivanaseNot Available
SanasthmaxChiesi
SanasthmylNot Available
VancenaseNot Available
VancerilNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Beclomethasone dipropionate monohydrate
77011-63-3
Thumb
  • InChI Key: QHQJZIXSVLFOHD-LYRZEVDOSA-N
  • Monoisotopic Mass: 538.2333459
  • Average Mass: 539.06
DBSALT001373
Categories
UNII5B307S63B2
CAS number5534-09-8
WeightAverage: 521.042
Monoisotopic: 520.222781245
Chemical FormulaC28H37ClO7
InChI KeyInChIKey=KUVIULQEHSCUHY-XYWKZLDCSA-N
InChI
InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1
IUPAC Name
2-[(1R,2S,10S,11S,13S,14R,15S,17S)-1-chloro-17-hydroxy-2,13,15-trimethyl-5-oxo-14-(propanoyloxy)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl]-2-oxoethyl propanoate
SMILES
[H][C@@]12C[[email protected]](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[[email protected]](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • Steroid ester
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Alpha-acyloxy ketone
  • Dicarboxylic acid or derivatives
  • Cyclic alcohol
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Chlorohydrin
  • Carboxylic acid ester
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl chloride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older, and in treating symptoms for allergic rhinitis (seasonal or perennial) in patients 12 years of age and older. Also being investigated for oral treatment in mild-to-moderate Crohn's disease of ileal or ileal-right colonic localisation and for "topical" use mild-to-moderate graft versus host disease.
PharmacodynamicsBeclometasone, a synthetic halogenated glucocorticoid with antiinflammatory and vasoconstrictive effects, is used for treating steroid-dependent asthma, allergic or nonallergic rhinitis, or recurrent nasal polyps.
Mechanism of actionUnbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. For the investigated use in the treatment of GvHD or Crohn's, beclometasone acts by binding to interleukin-13 to inhibit cytokines, which in turn inhibits inflammatory chemicals downstream.
Related Articles
AbsorptionMean peak plasma concentration was 88pg/ml at 0.5 hour
Volume of distribution

The steady state volume of distribution for beclomethasone dipropionate is 20 L, and for it’s active metabolite, beclomethasone-17-monopropionate, it is much larger at 424 L.

Protein binding87% to albumin and transcortin
Metabolism

Metabolism mediated via esterase enzymes that are found in most tissues. Undergoes rapid and extensive conversion to beclomenthasone-17-monopropionate (17-BMP) during absorption

Route of eliminationIrrespective of the route of administration (injection, oral or inhalation), BDP and its metabolites are mainly excreted in the feces. Less than 10% of the drug and its metabolites are excreted in the urine.
Half life2.8 hours
Clearance

High plasma clearance after intravenous administration (150 and 120 L/hour).

ToxicityThe acute toxicity of beclometasone dipropionate is low. The only harmful effect that follows inhalation of large amounts of the drug over a short period of time is suppression of hypothalamic-pituitary-adrenal (HPA) function. Chronic: The excessive use of beclometasone dipropionate over a long period could lead to adrenal suppression.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9904
Blood Brain Barrier+0.9851
Caco-2 permeable+0.5698
P-glycoprotein substrateSubstrate0.7529
P-glycoprotein inhibitor IInhibitor0.5986
P-glycoprotein inhibitor IINon-inhibitor0.7488
Renal organic cation transporterNon-inhibitor0.7907
CYP450 2C9 substrateNon-substrate0.8634
CYP450 2D6 substrateNon-substrate0.9174
CYP450 3A4 substrateSubstrate0.784
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.7516
CYP450 2C19 inhibitorNon-inhibitor0.9122
CYP450 3A4 inhibitorNon-inhibitor0.7875
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8577
Ames testNon AMES toxic0.938
CarcinogenicityNon-carcinogens0.914
BiodegradationNot ready biodegradable0.9932
Rat acute toxicity2.1115 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9456
hERG inhibition (predictor II)Non-inhibitor0.6054
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Schering corp sub schering plough corp
  • Schering corp
Packagers
Dosage forms
FormRouteStrength
Suspensionnasal50 mcg
Powderinhalation100 mcg
Powderinhalation200 mcg
Metered-dose aerosolinhalation250 mcg
Metered-dose aerosolinhalation; nasal50 mcg
Metered-dose aerosolinhalation; oral50 mcg
Capsuleinhalation100 mcg
Capsuleinhalation200 mcg
Spray, suspensionnasal42 ug/1
Metered-dose aerosol; suspensionnasal50 mcg
Creamtopical0.025 %
Creamtopical.025 %
Lotiontopical.025 %
Lotiontopical0.025 %
Aerosol, meterednasal40 ug/1
Aerosol, meterednasal80 ug/1
Aerosol, meteredrespiratory (inhalation)40 ug/1
Aerosol, meteredrespiratory (inhalation)80 ug/1
Metered-dose aerosolinhalation100 mcg
Metered-dose aerosolinhalation50 mcg
Spraynasal50 mcg
Metered-dose aerosolnasal50 mcg
Prices
Unit descriptionCostUnit
Beconase AQ 42 mcg/spray Suspension 25 gm Inhaler149.32USD inhaler
Beclomethasone dipro powder107.1USD g
Qvar 80 mcg/act Aerosol 7.3 gm Inhaler105.64USD inhaler
Qvar 40 mcg/act Aerosol 7.3 gm Inhaler87.5USD inhaler
Qvar 80 mcg inhaler19.05USD g
Qvar 40 mcg inhaler15.12USD g
Propaderm 250 mcg/g Cream0.46USD g
Qvar Cfc-Free 100 mcg/dose Metered Dose Aerosol0.33USD dose
Qvar Cfc-Free 50 mcg/dose Metered Dose Aerosol0.16USD dose
Apo-Beclomethasone 50 mcg/dose Metered Dose Spray0.06USD dose
Mylan-Beclo Aq. 50 mcg/dose Metered Dose Spray0.06USD dose
Nu-Beclomethasone 50 mcg/dose Metered Dose Spray0.06USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5776432 No1995-07-072015-07-07Us
US6446627 No1997-12-182017-12-18Us
US7780038 No2007-01-242027-01-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point117-120 °CNot Available
water solubility49.39 mg/LNot Available
logP1.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00208 mg/mLALOGPS
logP3.69ALOGPS
logP4.43ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)13.85ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area106.97 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity134.79 m3·mol-1ChemAxon
Polarizability54.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (11.1 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Taub, D., Wendler, N.L. and Slates, H.L.; US.Patent 3,345,387; October 3, 1967; assigned
to Merck & Co., Inc.

General References
  1. Willey RF, Milne LJ, Crompton GK, Grant IW: Beclomethasone dipropionate aerosol and oropharyngeal candidiasis. Br J Dis Chest. 1976 Jan;70(1):32-8. [PubMed:1259918 ]
  2. Salzman GA, Pyszczynski DR: Oropharyngeal candidiasis in patients treated with beclomethasone dipropionate delivered by metered-dose inhaler alone and with Aerochamber. J Allergy Clin Immunol. 1988 Feb;81(2):424-8. [PubMed:3339197 ]
  3. Fukushima C, Matsuse H, Tomari S, Obase Y, Miyazaki Y, Shimoda T, Kohno S: Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann Allergy Asthma Immunol. 2003 Jun;90(6):646-51. [PubMed:12839324 ]
  4. Astegiano M, Pagano N, Sapone N, Simondi D, Bertolusso L, Bresso F, Demarchi B, Pellicano R, Bonardi R, Marconi S, Rizzetto M: Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: Retrospective study. Biomed Pharmacother. 2007 Jul;61(6):370-6. Epub 2007 Mar 12. [PubMed:17399941 ]
  5. McDonald GB: Oral beclomethasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease following allogeneic hematopoietic cell transplantation. Expert Opin Investig Drugs. 2007 Oct;16(10):1709-24. [PubMed:17922633 ]
  6. Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, David D, Brunvand M, Berryman B, Abhyankar S, Bouvier M, McDonald GB: A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 2007 May 15;109(10):4557-63. Epub 2007 Jan 23. [PubMed:17244684 ]
  7. Castilla C, Perez-Simon JA, Sanchez-Guijo FM, Diez-Campelo M, Ocio E, Perez-Persona E, Lopez-Villar O, Vazquez L, Caballero D, San Miguel JF: Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD). Biol Blood Marrow Transplant. 2006 Sep;12(9):936-41. [PubMed:16920559 ]
External Links
ATC CodesR03BA01R03AK08D07CC04A07EA07R01AD01D07AC15
AHFS Codes
  • 52:08.08
  • 68:04.00
  • 84:06.00
PDB EntriesNot Available
FDA labelDownload (255 KB)
MSDSDownload (73.6 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with 1,10-Phenanthroline.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Beclomethasone dipropionate.
AldesleukinBeclomethasone dipropionate may decrease the antineoplastic activities of Aldesleukin.
Aluminum hydroxideThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Beclomethasone dipropionate.
AmiodaroneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Amiodarone.
Amphotericin BBeclomethasone dipropionate may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Atazanavir.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Beclomethasone dipropionate.
BazedoxifeneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Bazedoxifene.
BendroflumethiazideBeclomethasone dipropionate may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Beclomethasone dipropionate.
Bismuth SubcitrateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Boceprevir.
BumetanideBeclomethasone dipropionate may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Beclomethasone dipropionate.
Calcium carbonateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Calcium carbonate.
CarbamazepineThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Carbamazepine.
CeritinibBeclomethasone dipropionate may increase the hyperglycemic activities of Ceritinib.
CeritinibThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ceritinib.
ChlorothiazideBeclomethasone dipropionate may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Chlorotrianisene.
ChlorthalidoneBeclomethasone dipropionate may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Beclomethasone dipropionate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClarithromycinThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Beclomethasone dipropionate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Beclomethasone dipropionate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conjugated Equine EstrogensThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Beclomethasone dipropionate.
CoumaphosThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Coumaphos.
DarunavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Darunavir.
DecamethoniumThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Decamethonium.
DeferasiroxThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Deferasirox.
DemecariumThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Demecarium.
DichlorvosThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Dichlorvos.
DienestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Beclomethasone dipropionate.
DihydrotestosteroneBeclomethasone dipropionate may increase the fluid retaining activities of Dihydrotestosterone.
DonepezilThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Donepezil.
EchothiophateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Edrophonium.
EnzalutamideThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Enzalutamide.
EstradiolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estriol.
EstroneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estrone.
Etacrynic acidBeclomethasone dipropionate may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ethinyl Estradiol.
FenthionThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fenthion.
FluoxymesteroneBeclomethasone dipropionate may increase the fluid retaining activities of Fluoxymesterone.
FosaprepitantThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Fosphenytoin.
FurosemideBeclomethasone dipropionate may increase the hypokalemic activities of Furosemide.
GalantamineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ginkgo biloba.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Beclomethasone dipropionate.
HexestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Beclomethasone dipropionate.
HydrochlorothiazideBeclomethasone dipropionate may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazideBeclomethasone dipropionate may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Idelalisib.
IndacaterolIndacaterol may increase the hypokalemic activities of Beclomethasone dipropionate.
IndapamideBeclomethasone dipropionate may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Indinavir.
IsoflurophateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Beclomethasone dipropionate.
ItraconazoleThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ketoconazole.
LopinavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Lopinavir.
MagaldrateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Beclomethasone dipropionate.
MestranolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Mestranol.
MethyclothiazideBeclomethasone dipropionate may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneBeclomethasone dipropionate may increase the fluid retaining activities of Methyltestosterone.
MetolazoneBeclomethasone dipropionate may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Beclomethasone dipropionate can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Minaprine.
MitotaneThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Beclomethasone dipropionate.
NefazodoneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Neostigmine.
NevirapineThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Nicorandil.
OxandroloneBeclomethasone dipropionate may increase the fluid retaining activities of Oxandrolone.
OxymetholoneBeclomethasone dipropionate may increase the fluid retaining activities of Oxymetholone.
PentobarbitalThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Pentobarbital.
PhenobarbitalThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Beclomethasone dipropionate.
PhenytoinThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Physostigmine.
PiretanideBeclomethasone dipropionate may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Polyestradiol phosphate.
PolythiazideBeclomethasone dipropionate may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pyridostigmine.
QuinestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Quinestrol.
QuinethazoneBeclomethasone dipropionate may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rabies vaccine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Beclomethasone dipropionate.
RifabutinThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rivastigmine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Beclomethasone dipropionate.
SaquinavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Saquinavir.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Beclomethasone dipropionate.
StanozololBeclomethasone dipropionate may increase the fluid retaining activities of Stanozolol.
Synthetic Conjugated Estrogens, AThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Tacrine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Beclomethasone dipropionate.
TelaprevirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Telithromycin.
TestosteroneBeclomethasone dipropionate may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Tibolone.
TorasemideBeclomethasone dipropionate may increase the hypokalemic activities of Torasemide.
TrichlorfonThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Trichlorfon.
TrichlormethiazideBeclomethasone dipropionate may increase the hypokalemic activities of Trichlormethiazide.
TubocurarineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Tubocurarine.
VoriconazoleThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Voriconazole.
WarfarinBeclomethasone dipropionate may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Zeranol.
Food Interactions
  • No food effects were found when given with beclomethasone dipropionate.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Saklatvala J: Glucocorticoids: do we know how they work? Arthritis Res. 2002;4(3):146-50. Epub 2002 Jan 21. [PubMed:12010562 ]
  2. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850 ]
  3. Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, Adcock IM: Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med. 2005 Sep 15;172(6):704-12. Epub 2005 Apr 28. [PubMed:15860753 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Landyshev IuS, Grigorenko AA, Marikhina NS, Molochnaia SV: [A comparative assessment of the effect of different methods of glucocorticosteroid therapy on the hypophyseal-adrenal system in bronchial asthma patients]. Ter Arkh. 1995;67(3):43-7. [PubMed:7770804 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 02:27